Cargando…

Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation

To date, worldwide, atrial fibrillation is the most common cardiovascular disease in adults, with a prevalence of 2% to 4%. The trigger of the pathophysiological mechanism of arrhythmia includes several factors that sustain and exacerbate the disease. Ectopic electrical conductivity, associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Imbalzano, Egidio, Murdaca, Giuseppe, Orlando, Luana, Gigliotti-De Fazio, Marianna, Terranova, Dario, Tonacci, Alessandro, Gangemi, Sebastiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780784/
https://www.ncbi.nlm.nih.gov/pubmed/36555588
http://dx.doi.org/10.3390/ijms232415946
_version_ 1784856913740038144
author Imbalzano, Egidio
Murdaca, Giuseppe
Orlando, Luana
Gigliotti-De Fazio, Marianna
Terranova, Dario
Tonacci, Alessandro
Gangemi, Sebastiano
author_facet Imbalzano, Egidio
Murdaca, Giuseppe
Orlando, Luana
Gigliotti-De Fazio, Marianna
Terranova, Dario
Tonacci, Alessandro
Gangemi, Sebastiano
author_sort Imbalzano, Egidio
collection PubMed
description To date, worldwide, atrial fibrillation is the most common cardiovascular disease in adults, with a prevalence of 2% to 4%. The trigger of the pathophysiological mechanism of arrhythmia includes several factors that sustain and exacerbate the disease. Ectopic electrical conductivity, associated with the resulting atrial mechanical dysfunction, atrial remodeling, and fibrosis, promotes hypo-contractility and blood stasis, involving micro endothelial damage. This causes a significant local inflammatory reaction that feeds and sustains the arrhythmia. In our literature review, we evaluate the role of HMGB1 proteins, heat shock proteins, and S100 in the pathophysiology of atrial fibrillation, offering suggestions for possible new therapeutic strategies. We selected scientific publications on the specific topics “alarmins” and “atrial fibrillation” from PubMed. The nonsystematic review confirms the pivotal role of molecules such as S100 proteins, high-mobility group box-1, and heat shock proteins in the molecular pattern of atrial fibrillation. These results could be considered for new therapeutic opportunities, including inhibition of oxidative stress, evaluation of new anticoagulant drugs with novel therapeutic targets, molecular and genetic studies, and consideration of these alarmins as predictive or prognostic biomarkers of disease onset and severity.
format Online
Article
Text
id pubmed-9780784
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97807842022-12-24 Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation Imbalzano, Egidio Murdaca, Giuseppe Orlando, Luana Gigliotti-De Fazio, Marianna Terranova, Dario Tonacci, Alessandro Gangemi, Sebastiano Int J Mol Sci Review To date, worldwide, atrial fibrillation is the most common cardiovascular disease in adults, with a prevalence of 2% to 4%. The trigger of the pathophysiological mechanism of arrhythmia includes several factors that sustain and exacerbate the disease. Ectopic electrical conductivity, associated with the resulting atrial mechanical dysfunction, atrial remodeling, and fibrosis, promotes hypo-contractility and blood stasis, involving micro endothelial damage. This causes a significant local inflammatory reaction that feeds and sustains the arrhythmia. In our literature review, we evaluate the role of HMGB1 proteins, heat shock proteins, and S100 in the pathophysiology of atrial fibrillation, offering suggestions for possible new therapeutic strategies. We selected scientific publications on the specific topics “alarmins” and “atrial fibrillation” from PubMed. The nonsystematic review confirms the pivotal role of molecules such as S100 proteins, high-mobility group box-1, and heat shock proteins in the molecular pattern of atrial fibrillation. These results could be considered for new therapeutic opportunities, including inhibition of oxidative stress, evaluation of new anticoagulant drugs with novel therapeutic targets, molecular and genetic studies, and consideration of these alarmins as predictive or prognostic biomarkers of disease onset and severity. MDPI 2022-12-15 /pmc/articles/PMC9780784/ /pubmed/36555588 http://dx.doi.org/10.3390/ijms232415946 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Imbalzano, Egidio
Murdaca, Giuseppe
Orlando, Luana
Gigliotti-De Fazio, Marianna
Terranova, Dario
Tonacci, Alessandro
Gangemi, Sebastiano
Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation
title Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation
title_full Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation
title_fullStr Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation
title_full_unstemmed Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation
title_short Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation
title_sort alarmins as a possible target of future therapies for atrial fibrillation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780784/
https://www.ncbi.nlm.nih.gov/pubmed/36555588
http://dx.doi.org/10.3390/ijms232415946
work_keys_str_mv AT imbalzanoegidio alarminsasapossibletargetoffuturetherapiesforatrialfibrillation
AT murdacagiuseppe alarminsasapossibletargetoffuturetherapiesforatrialfibrillation
AT orlandoluana alarminsasapossibletargetoffuturetherapiesforatrialfibrillation
AT gigliottidefaziomarianna alarminsasapossibletargetoffuturetherapiesforatrialfibrillation
AT terranovadario alarminsasapossibletargetoffuturetherapiesforatrialfibrillation
AT tonaccialessandro alarminsasapossibletargetoffuturetherapiesforatrialfibrillation
AT gangemisebastiano alarminsasapossibletargetoffuturetherapiesforatrialfibrillation